Tea Polypeptide Ameliorates Diabetic Nephropathy through RAGE

Subscriber access provided by University of Sunderland

Bioactive Constituents, Metabolites, and Functions

Tea polypeptide ameliorates diabetic nephropathy through RAGE and NF-#B signaling pathway in type 2 diabetes mice Xuming Deng, Lingli Sun, Xingfei Lai, Limin Xiang, Qiuhua Li, Wenji Zhang, lingzhi zhang, and shili sun J. Agric. Food Chem., Just Accepted Manuscript • DOI: 10.1021/acs.jafc.8b04819 • Publication Date (Web): 25 Oct 2018 Downloaded from http://pubs.acs.org on October 25, 2018

Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

Page 1 of 50

Journal of Agricultural and Food Chemistry

1

Tea polypeptide ameliorates diabetic nephropathy through

2

RAGE and NF-κB signaling pathway in type 2 diabetes

3

mice

4

Xuming Deng1, 2#, Lingli Sun1,#, Xingfei Lai1, Limin Xiang1, Qiuhua Li1, Wenji Zhang1, ,

5

Lingzhi Zhang2,*, and Shili Sun1,*

6 7

1 Tea

8

Key Laboratory of Tea Plant Resources Innovation & Utilization, Dafeng Road NO.6, Tianhe

9

District, Guangzhou 510640, China

Research Institute, Guangdong Academy of Agricultural Sciences/ Guangdong Provincial

10

2

11

Guangzhou 510641, China

Department of Tea Science, College of Horticulture, South China Agricultural University,

12 13 14

# These

authors contributed equally to this work

15 16

*

17

[email protected] (Lingzhi Zhang)

Corresponding author: [email protected] (Shili Sun), Tel.: +86-20-8516-1045;

ACS Paragon Plus Environment


Page 2 of 50

2 of 50

19

Abstract: Diabetic nephropathy (DN) is a major complication of type 2 diabetes (T2D), which

20

is a key determinant of mortality in the diabetic patients. Developing new therapeutic drugs

21

which can not only control T2D but also prevent the development of DN is of great

22

significance. We studied the therapeutic potential of Cuiyu tea polypeptides (TP), natural

23

bioactive peptides isolated from a type of green tea, against DN and its underlying molecular

24

mechanisms. TP (1000 mg/kg bw/day, p.o.) administration for five weeks significantly reduced

25

the fasting blood glucose by 52.04

26

(HFD/STZ)-induced (30 mg/kg bw) diabetic mice. Compared to model group, the serum

27

insulin level of the TP group was decreased by 25.54 ± 6.06%, at the same time, the

28

HOMA-IR, HOMA-IS and lipid levels showed different degrees of recovery (p < 0.05).

29

Moreover, in TP group mice the total urinary protein, creatinine and urine nitrogen, all which

30

can reflect the damage degree of the glomerular filtration function in a certain extent, were

31

dramatically declined by 34.51 ± 2.65%, 42.24 ± 15.24% and 80.30 ± 6.01% compared to

32

model

33

PKCζ/JNK/NF-κB/TNF-α/iNOS and AGEs/RAGE/TGF-β1 pathways, upregulated the

34

expression of podocin in the glomeruli, and decreased the release of pro-inflammatory

35

cytokines. These results strongly indicate the therapeutic potential of TP against DN.

36

Keywords: tea polypeptide; type 2 diabetes; diabetic nephropathy; AGEs; NF-κB

group

respectively.

±

9.23% in the high fat diet/streptozocin

Mechanistically,

TP


stimulated

the

polyol

Page 3 of 50


3 of 50

37

INTRODUCTION

38

Type 2 diabetes (T2D) is thought to be a chronic metabolic disorder that currently affects

39

numerous of individuals worldwide, with its prevalence increasing at an alarming rate. In

40

addition, one-third of the individuals with T2D are undiagnosed, making it a global public

41

health concern1. Poorly controlled diabetes is associated with various complications including

42

nephropathy, atherosclerosis, retinopathy, and neuropathy2, 3, of which diabetic nephropathy

43

(DN) has probably the most detrimental consequences resulting in dialysis and heightened

44

cardiovascular risks4, 5. About 30% of the diabetic patients suffer from DN complications and

45

eventually undergoing kidney dialysis or transplantation6. The conspicuous pathological

46

changes were seen in DN, such as persistent albuminuria, altered creatinine clearance, tubule

47

interstitial fibrosis and glomerular sclerosis7.

48

The precise mechanisms by which dyslipidemia generates renal injury are yet to be elucidated.

49

However, studies indicate the involvement of multiple pathways and mechanisms in the

50

pathogenesis DN, which is also a major cause of diabetic mortality. Current evidence suggests

51

that chronic inflammation may be an important mediator of the occurrence and progression of

52

DN8. In DN model, persistent hyperglycemia activates the polyol pathway and accumulates

53

advanced glycation end products (AGEs), leading to the activation of multiple signaling

54

pathways like nuclear fraction kappa-beta (NF-κB), protein kinase C (PKC), and poly

55

ADP-ribose polymerase (PARP) signals9. The activation of NF-κB can promotes the secretion

56

of various pro-inflammatory cytokines, such as tumor necrosis factor α (TNF-α), interleukin 1β

57

(IL-1β), interleukin (IL-6) etc., leading to the deterioration of DN10. Besides, the progression of

58

DN is also influenced by factors like transforming growth factor (TGF-β1), angiotensin II and

59

c-Jun N-terminal kinases (JNK), which can stimulate glomerular and tubular fibrogenesis11, 12.

60

Furthermore, it has been reported that glucose-induced reactive oxygen species (ROS) induces ACS Paragon Plus Environment


Page 4 of 50

4 of 50

61

podocyte apoptosis and subsequent depletion which is an early trigger that leads to DN in

62

mouse type 1 and type 2 diabetic models13.

63

Therefore, efficiently prevent both the initiation as well as progression of DN is utmost

64

important issue in designing therapeutic strategies for diabetic patients. Previous studies have

65

shown that anti-inflammatory agents have ameliorative effects on glomerular injury in diabetic

66

rats, such as mycophenolate mofetil, retinoic acid etc.14. However, these conventional drugs

67

often have numerous side-effects. Hence, it is imperatives for a novel therapeutic strategy

68

targeting the specific molecular pathways of DN. Bioactive peptides obtained from medicinal

69

plants and dietary sources have recently gained wide attention for their potential in treating and

70

preventing various diseases. Peptides derived from the proteins dietary sources exhibit a wide

71

range of physiological and biological effects15, including the anti-diabetic effects of certain

72

polypeptides16-19. To the best of our knowledge, no study so far has reported anti-DN effects of

73

bioactive peptides derived from medicinal plants and dietary sources.

74

We isolated novel bioactive tea polypeptides (TPs) from the proteins of tea slag, and studied

75

their therapeutic effects on DN in type 2 diabetic ICR mouse model induced by high fat

76

diet/streptozotocin (HFD/STZ). We hypothesized that TPs protect the renal functions in

77

HFD/STZ T2D mice by inhibiting receptor for advanced glycation end-product (RAGE),

78

TGF-β1, podocin, protein kinase C zeta (PKCζ), c-Jun N-terminal kinases (JNK) and NF-κB

79

pro-inflammatory signaling pathways.

80

MATERIAL AND METHODS

81

Chemicals

82

Cuiyu green tea was obtained from Tea Research Institute, Guangdong Academy of

83

Agricultural Sciences in China. Streptozotocin (STZ) was procured from Sigma-Aldrich ACS Paragon Plus Environment

Page 5 of 50


5 of 50

84

(Sigma-Aldrich, USA). Commercial kits/reagents for biochemical assays were bought from

85

Jiancheng Inst. Biotechnology (Nanjing, China). All other chemicals and solvents were of

86

analytical grade.

87

Extraction of tea protein (TPR) and tea polypeptides (TP)

88

Tea protein (TPR) was obtained using the alkali method as previously described. Briefly, 1 g of

89

the Cuiyu green tea residue was crushed and extracted (liquid to solid ratio 20:1, v/v) with an

90

aqueous solution containing 2.5% pectinase at 45 oC (pH 3.4) for 3 h. The crude extract was

91

centrifuged at 1237 × g for 10 min and the supernatant was removed. The precipitate was

92

dissolved in 0.1 M NaOH (liquid to solid ratio 50:1, v/v) and further extracted at 90 oC for 100

93

min20. The mixture was cooled at room temperature and centrifuged (2200 × g, 10 min) to

94

remove the debris, and the proteins in the supernatant were precipitated by dropwise addition

95

of HCl for 0.5 h to a final pH of 2.5. The supernatant was removed by centrifugation, and the

96

precipitate was collected in dialysis bag (MWCO = 500 Da), dialyzed with deionized water for

97

24 h, and then centrifuged again to remove the supernatant. The protein precipitate was

98

re-dissolved in 75% acetone (solid-liquid ratio 1:6), shaken in an oscillator for 10 min

99

centrifuged and the steps were repeated once more. After a final wash with pure water, the

100

supernatant containing the acetone was removed, and the resulting TPR (300 mg, yield 30%)

101

was stored till analysis.

102

To obtain the TP, 1 g of the TPR preparation was digested with 50 ml acidic protease solution

103

(0.96 mg/ml, at pH 4) at 40 oC for 2 h, and centrifuged at 3155 × g for 15 min. The supernatant

104

was concentrated in a rotary evaporator, and freeze-dried into the TP (420 mg, yield 20%).

105

The Hitachi L-8900 Amino Acid Analyzer was used to determine the amino acid composition

106

in TPR and TP. The peptides in the TP preparation were characterized by LC-MS (liquid



Page 6 of 50

6 of 50

107

chromatography-mass spectrometry), and the data was processed using Mascot 2.3 (Matrix

108

Science) mass spectrometry software.

109

Determination of amino acid composition of TP and TPR

110

TP and TPR samples were hydrolyzed with 0.5 ml of 6 N HCl for 24 h at 112 °C, filtered

111

through a 0.45 µm membrane filter prior to analysis. 10 µl of treated samples were derivatized

112

6-aminoquinolyl-N-hydroxysuccinimidyl carbamate Waters AccQ·Fluor Reagent Kit. The

113

amino acids of samples were separated and detected using reversed phase high performance

114

liquid chromatography (Agilent Tech., USA) equipped with a Pico Tag column (3.9 × 300

115

mm, 5 µm, Waters). The amount of amino acids was calculated, based on the sample amino

116

acid peak area in comparison with that of standard. All analyses were repeated three times.

117

LC-MS/MS analysis of TP structure characterization

118

The LC-MS/MS analysis of TP was conducted in a TripleTOF5600 system (AB SCIEX)

119

combined with nanospray III ion source (AB SCIEX, USA). The hydrolysate fractions were

120

resuspended in mobile phase A (98% (v/v) water, 2% (v/v) acetonitrile, and 0.1% (v/v) of

121

formic acid) and 10 μL of sample was loaded on C18 nanoLC trap column(100 µm × 3 cm, C18,

122

3µm, 150Å) and washed by mobile phase A at 4 μL/min for 10 min. After 10 min of

123

preconcentration, the trap column was automatically switched in-line onto a ChromXP C18

124

column (75 μm × 15 cm, C18, 3μm, 120 Å). Mobile phase A contained 98% (v/v) water, 2%

125

(v/v) acetonitrile, and 0.1% (v/v) of formic acid. Mobile phase B contained 2% (v/v) water,

126

98% (v/v) acetonitrile, and 0.1% (v/v) of formic acid. Peptides were eluted with a linear


Page 7 of 50


7 of 50

127

gradient from 5% to 35% of solvent B over 90 min at a flow rate of 0.3 μL/min and running

128

temperature of 25 ºC. The following conditions were used to characterize the TP peptides:

129

spray voltage 2.5 kV, air curtain pressure 30 PSI, and atomization pressure 5 PSI. The data was

130

processed using Mascot 2.3 (Matrix Science) mass spectrometry software and homologous

131

protein analysis was performed with the protein database2 20160526 (15,566 sequences;

132

4,692,812 residues).（Figure S1）

133

Induction of T2D in a mouse model and treatment protocol

134

All animal experiments were performed in accordance with the laboratory animal care and use

135

guidelines strictly, and best efforts were made to minimize the pain of experimental animals.

136

The experiment protocols were approved by the Animal Care & Welfare Committee of Tea

137

Research Institute, Guangdong Academy of Agricultural Sciences. Sixty 8-week-old male ICR

138

mice were purchased from the Beijing Vital River Laboratory Animal Technology Co. Ltd. All

139

animals were maintained in a specific pathogen-free laboratory under the standard temperature

140

(23 ± 2 oC) and relative humidity (55 ± 5%) and a 12 h light/dark cycle, with ad libitum access

141

to food and water throughout the experiment.

142

T2D was induced by the streptozotocin (STZ) method as previously described21. After 1-week

143

acclimatization, the mice were randomized into the control and diabetic groups. The mice in

144

the normal control (NC) group were fed standard diet (protein 18%, fat 4%, carbohydrate 62%,

145

fiber 5%, minerals 8%, w: w; Beijing Huafukang Bioscience Co. Ltd, 1022) and those in the

146

diabetic group were given a high-fat diet (HFD; 16.46% protein, 45.65% fat, 37.89%

147

carbohydrates, as percentage of total kcal; Beijing Huafukang Bioscience Co. Ltd, D12451) ad

148

libitum till the end of the experiment. After five weeks of dietary manipulation, the HFD-fed



Page 8 of 50

8 of 50

149

mice were injected intraperitoneally with a single dose of STZ (30 mg/kg bw in citrate buffer

150

pH 4.4) once a week for three weeks without fasting. The control group mice were given

151

equivalent amounts of citrate buffer and normal saline. Five days after the last STZ injection,

152

the plasma glucose concentration of the model mice were measured after 12 h fasting period,

153

and a concentration of 11~18 mM confirmed T2D. No significant damage was seen in the

154

pancreas of these mice (Figure S2.)

155

For the treatment regimen, four groups of mice (n = 10 per group) were respectively given oral

156

doses of the following daily for 5 weeks: 1) NC – normal saline, 2) diabetic model control (MC)

157

– normal saline, 3) diabetic TP – 1000 mg/kg body weight TP, and 4) diabetic TPR – 1000

158

mg/kg body weight TPR. No side effects were observed based on the general behavior and

159

mental state of mice treated with TP and TPR. After the 5-week treatment, the serum alanine

160

aminotransferase (ALT) levels of the TP and TPR group mice were 11.0~31.0 IU/L. In

161

addition, these extracts had no toxic effects in normal healthy mice given the same doses as the

162

experimental mice (Figure S3.). The body weights, and total food and water consumption were

163

monitored weekly.

164

Preparation of serum and tissue homogenate

165

After the last TP/TPR dose, all mice were fasted overnight, and their urine samples were

166

collected the next day and maintained under mineral oil to avoid evaporation. The mice were

167

sacrificed by carbon dioxide asphyxiation, and blood samples were collected by cardiac

168

puncture. After leaving the samples undisturbed at room temperature for 30 min, the serum

169

was separated by centrifuging at 877 × g for 20 min and all serum samples were stored at -80

170

°C for further use. The animals were perfused trans-cardially through the ascending aorta with

171

saline to remove any residual blood clots, and then the left kidney and liver were rapidly

172

removed, weighed and washed thoroughly with phosphate buffer saline (PBS pH 7.4). The ACS Paragon Plus Environment

Page 9 of 50


9 of 50

173

tissues were homogenized in ice-cold PBS, and stored in liquid nitrogen for further

174

biochemical and molecular assays. The right kidney was also removed and fixed in 10%

175

buffered formalin, and embedded in paraffin for histopathological examination.

176

Serum biochemical analysis

177

Blood was collected from the tail veins once a week during the 5-week treatment period after

178

12 h fasting, and the levels of fasting blood glucose (FGB) were measured using commercial

179

assay kits (Nanjing, China). In addition, total cholesterol (TC), triglyceride (TG), low-density

180

lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) levels were

181

measured using an Automatic Analyzer (Icubio, China). Urine was also collected on a weekly

182

basis 24 h after each treatment, and total urinary protein levels were measured using suitable

183

kits. A homeostasis model assessment of insulin resistance (HOMA-IR) and insulin sensitivity

184

(HOMA-IS) was used to evaluate insulin resistance and sensitivity respectively, with the

185

following formulae: HOMA-IR = fasting serum insulin (mU/ml) × fasting plasma glucose

186

(mM)/22.5, and HOMA-IS = 1/[fasting plasma glucose (mM) × fasting serum insulin (mU/ml)]

187

22.

188

Enzyme-linked immunosorbent assay (ELISA)

189

Insulin and AGEs levels in the serum and kidney were measured using commercial ELISA kits

190

(Insulin: Sigma-Aldrich, USA; AGEs: Abcam, Cambridge, UK) according to the

191

manufacturer’s instructions. Briefly, take 100 mg kidney tissue in EP tube with 1 ml of PBS

192

(PH, 7.4), homogenized using a homogenizer (OMNI International, USA), after centrifuging

193

(11187 × g, 5 min), the supernatant was collected and assayed immediately.

194

Western blotting



Page 10 of 50

10 of 50

195

The kidney tissues were homogenized on ice for 10 s using a polytron tissue homogenizer, and

196

then lysed in 0.5 ml ice-cold lysis buffer [50 mmol/L Tris (pH 7.4), 150 mmol/L NaCl, 1%

197

Triton X-100, 1% sodium deoxycholate, 0.1% SDS, proteinase inhibitor (Roche Applied

198

Science, Germany) and phosphatase inhibitor (Sigma-Aldrich, USA)]. The tissue samples were

199

cracked use an ultrasonic dismembrator (Fisher Scientific, USA) at the speed of 2 greed for 30

200

pulses, and stored at -80 °C for further analysis. Lowry method was used to determine the

201

protein concentration of samples, and 50 µg of each sample was boiled in sodium dodecyl

202

sulfate (SDS) sample loading buffer for 5 min. The samples were loaded into 10%

203

SDS–polyacrylamide gel, and after electrophoresis for 1.5 h, were transferred to PVDF

204

membranes (Millipore, USA). Block the membranes with 5% skim milk or BSA in TBST

205

(Tris-buffered saline containing 0.1% Tween 20) at room temperature for 2 h. And then the

206

membranes were incubated overnight at 4 °C with rabbit polyclonal antibodies against JNK,

207

p-JNK, PKCζ p-PKCζ, NF-κB, p-NF-κB, inducible nitric oxide synthases (iNOS), TNF-α (all

208

from Cell Signaling Technology), rabbit polyclonal antibodies (1:500) against Podocin,

209

RAGE, TGF-β1 (all from Boster, China), and mouse polyclonal anti-β-actin (1:2000;

210

Sigma-Aldrich). After washing thrice with TBST (5 min), the membrane was incubated with

211

anti-mouse or anti-rabbit immunoglobulin G antibody conjugated to horseradish peroxidase

212

(1:4000; Cell Signaling Technology, USA) for 2 h at room temperature. The positive signals

213

were visualized using chemiluminiscence (ECL) detection kit (Thermo Scientific, USA),

214

imaged with Chemi Doc system (Bio-Rad, USA), and quantified by NIH IMAGEJ software

215

(Bethesda, MD, USA). The protein expression levels of p-PKCζ, p-JNK and p-NF-κB were

216

normalized to that of PKCζ, JNK and NF-κB, while iNOS, Podocin, RAGE, TGF-β1 and

217

TNF-α levels were normalized to β-actin (internal control).

218

Histology and immunohistochemistry (IHC) ACS Paragon Plus Environment

Page 11 of 50


11 of 50

219

Formalin fixed kidney tissues were paraffin embedded, cut into sections, and stained with

220

hematoxylin and eosin (HE) using standard protocols. For IHC, the sections were

221

de-paraffinized with xylene for 2 times (each time more than 5 min), quenched with 3%

222

hydrogen peroxide for 15 min, washed twice with PBS (PH 7.4), and then blocked for 1 h with

223

10% normal goat serum (Invitrogen, USA) at room temperature. The sections were then

224

incubated overnight at 4 °C with the primary antibodies, and then with the IHC Detection

225

Reagent (Boster) against rabbit IgG for 30 min at room temperature. Developed the color using

226

3, 30- diaminobenzidine (DAB), and photographed the images under a BX60 microscope

227

(Olympus, Japan) fitted with a camera.

228

Statistical analysis

229

The results are presented as mean ± SEM. The means were compared by one-way ANOVA

230

and Tukey’s test using the GraphPad Prism 7.0 for Windows (GraphPad Software Inc., San

231

Diego, CA, USA). The level of confidence required for significance was set at p ≤ 0.05. All

232

experiments were performed at least triplicates.

233

RESULTS

234

The amino acid composition of TP

235

As shown in Table 1, although the total content of hydrolyzed amino acids was higher in TPR

236

compared to TP (38.0 g/100 g vs 14.8 g/100 g), its total content of free amino acids was lower

237

than that of TP (0.16 g/100 g vs 3.89 g/100 g).

238

LC-MS/MS analysis of TP structure characterization

239

The peptides in the TP were identified according to the observed total ion chromatogram

240

(Figure S1) and MS/MS spectroscopy data. Protein score of the TP matched to that of ACS Paragon Plus Environment


Page 12 of 50

12 of 50

241

Flavonoids-3'-hydroxylase, Chloroplast stroma ascorbate peroxidase, Arginine decarboxylase,

242

RNA polymerase II accessory factor and Beta-glucosidase 5 GH3 family. Thirteen major

243

peptide components were sequenced. These peptides range from 7 to 31 residues. Specific

244

peptide information is shown in Table 2.

245

Effect of TP on body weight, water consumption, FBG and serum insulin

246

No significant difference in the pre-treatment blood glucose levels across the different groups.

247

Following HFD/STZ diabetes induction, the mice developed significant hyperglycemia with

248

steady increase in the levels of blood glucose (~10 mM) compared to the normal group. The

249

mice in all treatment groups had similar level of FBG, significantly higher than that of NC

250

group (Fig.1A; p < 0.01). While treatment with TP or TPR did not significantly affect FBG

251

levels during the first week after administration, the latter began to decline after three weeks of

252

treatment. After 5 weeks, FBG levels decreased by 52.04 ± 9.23% (from 16.3 mM to 8.46

253

mM) in the TP group, compared to that of the MC group (~15.61 mM). Although TPR also

254

alleviated the hyperglycemic symptoms, the FBG of the TP group was lower by 2.75 mM

255

compared to the TPR group (Fig.1A). The serum insulin level of the TP group was reduced by

256

25.54 ± 6.06% compared to the MC group (6.36 ± 0.03 vs 8.59 ± 0.49mU/L, Fig. 1B), while

257

TPR did not have a significant effect (8.36 ± 0.34, Fig. 1B). Furthermore, the body weight of

258

the T2D mice was significantly lower than that of normal mice (Fig. 1C), and TP and TPR

259

treatment significantly reduced water intake but had no effect on food consumption in the

260

diabetic mice (Fig. 1D).

261

Effects of TP on insulin tolerance and lipid levels in serum

262

To further evaluate the ameliorative effects of TP on the diabetic phenotype, we analyzed the

263

HOMA-IR, HOMA-IS and lipid levels in mice serum (Fig. 2). Compared to the MC group, the ACS Paragon Plus Environment

Page 13 of 50


13 of 50

264

HOMA-IR values were significantly lower in all treatment groups (p < 0.05; Fig. 2A).

265

Furthermore, a significant increase in HOMA-IS values was observed in the TP and TPR

266

groups relative to the MC group (p < 0.01; Fig. 2B). These results indicated that TP can

267

ameliorate insulin resistance in diabetic mice. The effects of TP and TPR on different serum

268

biochemical parameters are shown in Fig. 2C-F. The TC and TG levels were considerably

269

higher in the MC group compared to the controls (p < 0.05), and were both significantly

270

downregulated by TP and TPR treatment (p < 0.05 for both), with serum TG levels decreasing

271

by 75.0%~86.1% (Fig. 2C, D). The T2D mice exhibited significant escalation in the

272

LDL-cholesterol (p < 0.01) levels with simultaneous depletion of HDL-cholesterol (p < 0.01)

273

compared to the normal mice, and while HDL was increased by 14.3%~17.6% to almost

274

normal levels following TP and TPR treatment (Fig. 2E), LDL was reduced by 44.8% by TP

275

(Fig. 2F) in the diabetic mice.

276

Renal dysfunction of T2D mice was markedly ameliorated by TP

277

The diabetic mice exhibited a significant increase in renal mass and volume, and TP treatment

278

significantly restored both kidney appearance and kidney mass to body mass ratio to near

279

normal status (Fig. 3A, B). In addition, a 3-5 fold increase was observed in total urinary protein

280

excretion in the MC mice compared to the control mice, which were restored to baseline levels

281

by TP and TPR (p < 0.01; Fig. 3C) with greater effect of TP. Furthermore, diabetes-induced

282

histopathological damage of the kidneys was alleviated by TP and TPR (Fig. 3D). Since the

283

glomerular endothelial cells are vital for the functional maintenance of glomerular filtration,

284

we also analyzed the number of cells in the glomeruli (Fig. 3E). The MC mice showed

285

significantly fewer glomerular cells compared to the control mice (26.2 ± 2.18 vs 52.00 ± 3.59

286

cells per glomerulus, p < 0.01), which was reversed by both TP (39.00 ± 1.14 cells per



Page 14 of 50

14 of 50

287

glomerulus) and TPR (35.20 ± 1.36 cells per glomerulus; p < 0.05 for both vs MC group, Fig.

288

3E). In addition, all treated groups had significantly lower glomerular hypertrophy (3038.05 ±

289

129.75 μm2 for TP; 3194.54 ± 100.47 μm2 for TPR; 4330.83 ± 208.33 μm2 for MC; 2478.21 ±

290

116.68 μm2 for NC; p < 0.05, Fig. 3F). Creatinine, urine nitrogen and the ratio of the two can

291

reflect the damage degree of the glomerular filtration function in a certain extent. Significant

292

decreases in creatinine and urine nitrogen in serum were observed in TP or TPR group

293

compared to MC group (Fig. 4).

294

Podocytes express various cytoskeletal proteins e.g. the slit diaphragm (SD)-localized podocin

295

which maintain the SD and foot processes integrity, and any disruption in these proteins result

296

in podocyte injury, foot process effacement and albuminuria. As shown in Fig. 5, podocin

297

levels were significantly decreased in diabetic mice, while TP and TPR treatment significantly

298

increased the same (p < 0.05).

299

TP attenuated renal AGEs accumulation and re-established normal expression of RAGE

300

Interaction between AGEs and their receptors (RAGE) play important roles in the initiation

301

and progression of diabetes mellitus and diabetic complications23,

302

AGEs in diabetic patients may be an important mediator of the detrimental effect of

303

hyperglycemia. In addition, glomerular IgG deposition is also seen in diabetes due to the

304

increased expression levels of circulating antibody targeted modified proteins. Therefore, the

305

protective effects of TP on DN could be due to the reversal of AGEs accumulation. Higher

306

levels of AGEs were seen in the kidneys of MC mice (4.64 ± 0.27-fold increase compared to

307

NC group, p < 0.01), which was attenuated not only by TPR (1.63 ± 0.06-fold increase

308

compared to NC group; p < 0.05 vs MC group), but also by TP (1.44 ± 0.03-fold increase

309

compared to NC group; p < 0.05 vs MC group) (Fig. 6). Given that AGEs exert inflammatory


24.

The accumulation of

Page 15 of 50


15 of 50

310

and oxidative effects in DN via RAGE, we also analyzed the renal expression of RAGE.

311

Compared to the NC group, both AGEs and RAGE were significantly upregulated in the

312

diabetic kidney, and decreased following TP treatment (Fig. 6).

313

TP improved renal fibrosis through reducing TGF-β1 production

314

The pro-inflammatory cytokine TGF-β1 is regulated by AGEs, and plays an important role in

315

kidney diseases, including DN25. Therefore, we further examined the possible involvement of

316

the TGF-β1 signaling pathway in the ameliorative effects of TP on DN pathologies (Fig. 7).

317

Renal expression of TGF-β1 significantly decreased in the diabetic mice treated with TP (0.59

318

± 0.07 vs 2.01 ± 0.05 fold increase compared to NC group) as well as TPR (0.70 ± 0.01

319

nmol/mg of protein) (p < 0.05; Fig. 7B, C). In addition, a strong in situ expression of TGF-β1

320

was seen in the kidney biopsies of diabetic mice, which was almost undetectable in the

321

drug-treated mice (Fig. 7A, D).

322

Effects of TP on the NF-κB signaling pathway in kidneys

323

Studies show the central role of inflammatory pathways in the development of various diabetic

324

complications. NF-κB pathway is activated in DN model26, and transcriptionally activates

325

genes encoding inflammatory and proliferative proteins involved in DN pathogenesis27. A

326

significant up-regulation in NF-κB phosphorylation was observed in the kidney homogenates

327

of T2D mice when compared to that of NC mice (p < 0.01; Fig. 8). Although both TP and TPR

328

treatment down-regulated (p < 0.01) p-NF-κB levels, the effect of TP was more evident. The

329

expression levels of renal p-PKCζ and p-JNK, which are known to activate NF-κB, were

330

significantly higher in the diabetic mice compared to NC mice (p < 0.01; Fig. 8). TP and TPR

331

treatment significantly restored p-PKCζ and p-JNK to baseline levels (p < 0.05), with TP

332

showing a greater effect than TPR on p-JNK levels (Fig. 8C). Furthermore, in MC group mice, ACS Paragon Plus Environment


Page 16 of 50

16 of 50

333

a significant escalation in the levels of TNF-α and iNOS (p < 0.01), which were restored by TP

334

and TPR treatments (Fig. 9).

335

DISCUSSION

336

Diabetic nephropathy (DN), as a serious complication of type 2 diabetes (T2D), is one of the

337

leading causes of death in diabetic patients28. Current therapy for diabetes focuses on the

338

intensive control of blood glucose, but neglects the renal complications associated with

339

hyperglycemia. We found that T2D mice modeled by a 6-week long HFD/STZ induction

340

exhibited hyperglycemia, insulin resistance, renal structural and function abnormalities and

341

increased renal inflammation, all of which are the critical features of DN. These results are in

342

agreement with Danda et al (2005), who successfully developed a model of DN in HFD/STZ

343

induced T2D rats, with hyperglycemia, insulin resistance and renal dysfunction and structural

344

remodeling, which simulated the human disease29. TP treatment however significantly

345

improved the levels of FBG, HOMA-IR, HOMA-IS and serum lipids in the T2D mice, and

346

significantly restored the serum and urine parameters to baseline values.

347

Hyperglycemia-induced formation of AGEs is an important source of oxidative free radicals9.

348

AGEs stimulate several cellular responses such as inflammation, matrix production and

349

fibrogenesis, by binding to their specific receptors (RAGE) expressed on various cells, like the

350

glomerular mesangial cells30. Moreover, the immune complex deposition in the glomerular

351

have been considered associated with an increased level of circulating antibodies against

352

AGEs, and may play a pivotal role in albuminuria and tissue injury31, 32. TP inhibited AGE

353

accumulation, downregulated RAGE expression, and decreased glomerular IgG deposition.

354

Therefore, the inhibition of AGEs formation by TP may largely contribute to the amelioration


Page 17 of 50


17 of 50

355

of DN symptoms. Furthermore, in DN models, gene deletion or pharmacologic blockade of

356

RAGE can effectively prevent early renal dysfunction and glomerular structure changes33.

357

The AGEs-RAGE system upregulates TGF-β1, a potent pro-fibrotic cytokine involved in the

358

progression of diabetic renal tubule interstitial fibrosis, in glomerular mesangial cells34. The

359

expression level of TGF-β1 is increased in diabetic patients35, 36, as well as in experimental

360

models of diabetic kidney disease37-39. It stimulates the production of several extracellular

361

matrix (ECM) proteins that accumulate in the podocytes of the diabetic kidney, such as type IV

362

collagen, fibronectin and laminin, and further increases TGF-β production by the podocytes

363

and mesangial cells40-42. In the present study, the expression levels of TGF-β1 increased

364

significantly in the renal tissue of MC mice, while treatment with TP significantly reduced its

365

levels.

366

Podocytes are glomerular cells occurring specifically in the Bowman's capsule that wraps

367

around capillaries of the glomerulus, and are attached to the lateral side of the glomerular

368

basement membrane (GBM). The cells are inter-connected by the slit diaphragm (SD) of

369

podocytes to form a barrier against protein loss43,

370

nephrin, cluster of differentiation 2-associated protein (CD2AP) and other related proteins, and

371

proteinuria is initiated with podocin downregulation, followed by that of nephrin and CD2AP.

372

Podocin plays an important role in stabilizing nephrin and CD2AP in the SD. TP

373

administration reduced albuminuria, attenuated pathological renal damage and restored

374

glomerular podocin levels in the T2D mice. These findings indicate that TP relieves renal

375

dysfunction via its protective effects on the glomerular podocytes.

376

Recent studies focusing on the cellular and molecular etiologies of DN have gauged

377

inflammation as its key patho-physiological mechanism26. Hyperglycemic conditions are

378

known to increase macrophage infiltration and activation, which further aggravate

44.

The SD mainly consists of podocin,



Page 18 of 50

18 of 50

379

hyperglycemia and contribute to the development of renal injury and sclerosis45. NF- κ B, a

380

ubiquitous transcription factor, is a major regulator of the inflammatory response and is

381

activated by many DN-specific stimuli. Furthermore, growing evidence indicates that NF-κB is

382

central to many interrelated pathways involved in the structural and functional changes

383

observed in DN, such as activation of the renin–angiotensin system, AGE accumulation, and

384

NADPH-dependent oxidative stress10, 46. Schmid et al correlated the upregulation of NF-κB

385

with the inflammatory response in DN patients47, and activation of NF- κ B has also been

386

observed in the renal cortical tissue of animals with STZ-induced diabetes48. Consistent with

387

these findings, we found a significant increase in the nuclear translocation of NF-κB p65 in the

388

T2D mice, which was effectively inhibited by TP.

389

The activated NF- κ B, i.e. free NF- κ B p65 subunit, transcriptionally activates downstream

390

effector genes, such as those encoding TGF-β1, TNF-α, iNOS, pro-inflammatory cytokines and

391

chemokines49. PKC, JNK50, and PKCζ51 activate NF-κB in different cell types. JNK, which

392

regulates environmental stress and inflammatory cytokines52, triggers insulin resistance by

393

phosphorylating the c-Jun protein. This causes insulin deficiency and ultimately an increase in

394

glucose levels, thereby contributing to the progression of DN53,

395

upregulation of TNF-α and iNOS, as well as the activation of PKCζ and JNK in the diabetic

396

kidneys, indicating a possible post-transcriptional mechanism of suppressing inflammation and

397

fibrosis.

398

At the same time, the tea polypeptide extraction yield is relatively low, and the extraction

399

process needs to be optimized to improve the yield of tea polypeptide. TP is a kind of

400

polypeptide mixture containing peptides with different molecular weights, which is the reason

401

for the high dose (1000 mg/kg BW, p.o.) used in this study. Compared with the monomer

402

compounds, the mixture experiment materials need higher dose55, 56. The substance and exact ACS Paragon Plus Environment

54.

TP inhibited the

Page 19 of 50


19 of 50

403

structure of TP involved in the above functions remains to be elucidated. At present, there have

404

been no specific drugs that really target diabetic nephropathy. Current treatments have been

405

mainly focused on managing blood glucose and insulin levels57. Thus, we are not set positive

406

control group in this study. Therefore, a profound study and discussion on these problems

407

remain important topics in the further of our research.

408

Taken together, TP attenuated pathological renal damage via hypoglycemic, insulin-sensitizing

409

and anti-inflammatory in the DN mouse model of HFD/STZ-induced T2D. The hypoglycemic

410

and

411

AGEs/RAGE/TGF-β1 signaling pathway, and the upregulation of podocin in the glomeruli. TP

412

specifically suppressed the NF- κ B pathway-mediated renal dysfunction in these mice,

413

indicating that the NF- κB pathway is a potential therapeutic target in DN. Although there is

414

unable to compare the efficacy of TP with clinical drugs, tea polypeptide, as a natural and

415

nontoxic polypeptide, is still a promising candidate for the treatment diabetic nephropathy.

416

Acknowledgments: This work was supported by the National Natural Science Foundation of

417

China (NO. 81803236, 31800295). Guangdong Science and Technology program (NO.

418

2017A070702004, 2016B090918118, 2017A020224015), Natural Science Foundation of

419

Guangdong Province (NO. 2017A030310504), the Guangdong Provincial Agriculture

420

Department program (NO. 2017LM2151), Science and Technology Board of Qingyuan (NO.

421

2016A005), the President Foundation of Guangdong Academy of Agricultural Sciences (NO.

422

201534 and 201720) and the Open Fund of Guangdong Provincial Key Laboratory of Tea

423

Plant Resources Innovation & Utilization (NO. 201702).

insulin-sensitizing

effects

were

likely

mediated


by

stimulation

of

the


Page 20 of 50

20 of 50

424

Author Contributions: Lingzhi Zhang, Lingli Sun, Xingfei Lai and Shili Sun conceived and

425

designed the experiments. Xuming Deng performed the experiments. Xuming Deng and Limin

426

Xiang analyzed the data. Xingfei Lai, Qiuhua Li and Wenji Zhang contributed reagents and

427

participated in animal surgery. Xuming Deng wrote the paper, and Lingli Sun and Shili Sun

428

critically revised the manuscript. All authors approved the final version of the manuscript.

429

Conflicts of Interest: The authors declare no conflict of interest.

430

Supplementary Materials: The following are available online at www.mdpi.com/link, Figure

431

S1: The total ion chromatogram of TP. Figure S2: IHC staining of pancreas in all experimental

432

groups. Figure S3: No toxic effect of TP and TPR in normal healthy mice.

433 434

References

435

(1) Wang, X.; Bao, W.; Liu, J.; OuYang, Y. Y.; Wang, D.; Rong, S.; Xiao, X.; Shan, Z. L.;

436

Zhang, Y.; Yao P.; Liu, L. G. Inflammatory Markers and Risk of Type 2 Diabetes A

437

systematic review and meta-analysis, Diabetes Care, 2013, 36, 166-175.

438 439

(2) Hu, F. B. Obesity and mortality: watch your waist, not just your weight, Archives of internal medicine, 2007, 167, 875-876.

440

(3) Lavie, C. J.; Osman, A. F.; Milani R. V.; Mehra, M. R. Body composition and prognosis in

441

chronic systolic heart failure: the obesity paradox, The American journal of cardiology,

442

2003, 91, 891-894.


Page 21 of 50


21 of 50

443

(4) Valmadrid, C. T.; Klein, R.; Moss, S. E.; Klein, B. E. The risk of cardiovascular disease

444

mortality associated with microalbuminuria and gross proteinuria in persons with

445

older-onset diabetes mellitus, Archives of internal medicine, 2000, 160, 1093-1100.

446

(5) Gerstein, H. C.; Mann, J. F.; Yi, Q.; Zinman, B.; Dinneen, S. F.; Hoogwerf, B.; Halle, J. P.;

447

Young, J.; Rashkow, A.; Joyce, C.; Nawaz, S.; Yusuf, S.; Investigators, H. S. Albuminuria

448

and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic

449

individuals, Jama, 2001, 286, 421-426.

450 451

(6) Krolewski, M.; Eggers P. W.; Warram, J. H. Magnitude of end-stage renal disease in IDDM: a 35 year follow-up study, Kidney international, 1996, 50, 2041-2046.

452

(7) Dekkers, C. C. J.; Wheeler, D. C.; Sjöström, C. D.; Stefansson, B. V.; Cain, V.; Heerspink,

453

H. J. L. Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients

454

with type 2 diabetes and Stages 3b-4 chronic kidney disease, Nephrol Dial Transplant.

455

2018, 33, 1-7.

456

(8) Du, Y. G.; Zhang, K. N.; Gao, Z. L.; Dai, F.; Wu X. X.; Chai, K. F. Tangshen formula

457

improves inflammation in renal tissue of diabetic nephropathy through SIRT1/NF-kappaB

458

pathway, Experimental and therapeutic medicine, 2018, 15, 2156-2164.

459

(9) Bhattacharjee, N.; Barma, S.; Konwar, N.; Dewanjee S.; Manna, P. Mechanistic insight of

460

diabetic nephropathy and its pharmacotherapeutic targets: An update, Eur J Pharmacol,

461

2016, 791, 8-24.



Page 22 of 50

22 of 50

462

(10) Cooper, M. E. Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy, Diabetologia, 2001, 44, 1957-1972.

463 464

(11) Ziyadeh, F. N. Mediators of diabetic renal disease: The case for TGF-beta as the major mediator, J Am Soc Nephrol, 2004, 15, S55-S57.

465 466

(12) Ziyadeh F. N.; Sharma, K. Overview: Combating diabetic nephropathy, J Am Soc Nephrol, 2003, 14, 1355-1357.

467 468

(13) Susztak, K.; Raff, A. C.; Schiffer, M.; Bottinger, E. P. Glucose-induced reactive oxygen

469

species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic

470

nephropathy, Diabetes, 2006, 55, 225-233.

471

(14)

Luis-Rodriguez,

D.;

Martinez-Castelao,

A.;

Gorriz,

J.

L.;

De-Alvaro,

F.;

472

Navarro-Gonzalez, J. F. Pathophysiological role and therapeutic implications of

473

inflammation in diabetic nephropathy, World journal of diabetes, 2012, 3, 7-18.

474 475

(15) Udenigwe C. C.; Aluko, R. E. Food protein-derived bioactive peptides: production, processing, and potential health benefits, Journal of food science, 2012, 77, R11-24.

476

(16) de la Rosa, A. P. B.; Montoya, A. B.; Martinez-Cuevas, P.; Hernandez-Ledesma, B.;

477

Leon-Galvan, M. F.; De Leon-Rodriguez, A.; Gonzalez, C. Tryptic amaranth glutelin

478

digests induce endothelial nitric oxide production through inhibition of ACE:

479

Antihypertensive role of amaranth peptides, Nitric Oxide-Biol Ch, 2010, 23, 106-111.


Page 23 of 50


23 of 50

480

(17) Moller, N. P.; Scholz-Ahrens, K. E.; Roos, N.; Schrezenmeir, J. Bioactive peptides and

481

proteins from foods: indication for health effects, European journal of nutrition, 2008, 47,

482

171-182.

483

(18) Velarde-Salcedo, A. J.; Barrera-Pacheco, A.; Lara-Gonzalez, S.; Montero-Moran, G. M.

484

A. Diaz-Gois, E. Gonzalez de Mejia and A. P. Barba de la Rosa, In vitro inhibition of

485

dipeptidyl peptidase IV by peptides derived from the hydrolysis of amaranth (Amaranthus

486

hypochondriacus L.) proteins, Food chemistry, 2013, 136, 758-764.

487

(19) Estrada-Salas, P. A.; Montero-Moran, G. M.; Martinez-Cuevas, P. P.; Gonzalez, C.; Barba

488

de la Rosa, A. P. Characterization of antidiabetic and antihypertensive properties of canary

489

seed (Phalaris canariensis L.) peptides, Journal of agricultural and food chemistry, 2014,

490

62, 427-433.

491

(20) CUI, Q.; NI, X.; ZENG, L.; TU, Z.; LI, J.; SUN, K.; CHEN, X.; LI, X. Optimization of

492

Protein Extraction and Decoloration Conditions for Tea Residues, Horticultural Plant

493

Journal, 2017, 3, 172-176.

494

(21) Srinivasan, K.; Viswanad, B.; Asrat, L.; Kaul, C. L.; Ramarao, P. Combination of high-fat

495

diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and

496

pharmacological screening, Pharmacological research, 2005, 52, 313-320.

497

(22) Matthews, D. R.; Hosker, J. P.; Rudenski,; Naylor, B. A.; Treacher, D. F.; Turner, R. C.

498

Homeostasis model assessment: insulin resistance and beta-cell function from fasting

499

plasma glucose and insulin concentrations in man, Diabetologia, 1985, 28, 412-419.



Page 24 of 50

24 of 50

500

(23) Valko, M.; Leibfritz, D.; Moncol, J.; Cronin, M. T.; Mazur, M.; Telser, J. Free radicals

501

and antioxidants in normal physiological functions and human disease, The international

502

journal of biochemistry & cell biology, 2007, 39, 44-84.

503 504

(24) Yamagishi, S. Role of advanced glycation end products (AGEs) in osteoporosis in diabetes, Current drug targets, 2011, 12, 2096-2102.

505

(25) Miyauchi, K.; Takiyama, Y.; Honjyo, J.; Tateno, M. Haneda, M. Upregulated IL-18

506

expression in type 2 diabetic subjects with nephropathy: TGF-beta1 enhanced IL-18

507

expression in human renal proximal tubular epithelial cells, Diabetes research and clinical

508

practice, 2009, 83, 190-199.

509

(26) Navarro-Gonzalez, J. F.; Mora-Fernandez, C.; Muros de Fuentes, M.; Garcia-Perez, J.

510

Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy, Nature

511

reviews. Nephrology, 2011, 7, 327-340.

512

(27) Coimbra, T. M.; Janssen, U.; Grone, H. J.; Ostendorf, T.; Kunter, U.; Schmidt, H.;

513

Brabant, G.; Floege, J. Early events leading to renal injury in obese Zucker (fatty) rats with

514

type II diabetes, Kidney international, 2000, 57, 167-182.

515 516

(28) Kuhad, A.; Chopra, K. Attenuation of diabetic nephropathy by tocotrienol: involvement of NF-κB signaling pathway, Life Sci, 2009, 84, 296-301.

517

(29) Danda, R. S.; Habiba, N. M.; Rincon-Choles, H.; Bhandari, B. K.; Barnes, J. L.; Abboud,

518

H. E.; Pergola, P. E. Kidney involvement in a nongenetic rat model of type 2 diabetes,

519

Kidney Int, 2005, 68, 2562-2571.


Page 25 of 50


25 of 50

520

(30)Sakurai, S.; Yonekura, H.; Yamamoto, Y.; Watanabe, T.; Tanaka, N.; Li, H.; Rahman, A.

521

K.; Myint, K. M.; Kim, C. H.; Yamamoto, H. The AGE-RAGE system and diabetic

522

nephropathy, J Am Soc Nephrol, 2003, 14, S259-263.

523

(31) Lee, S. M.; Graham, A. Early immunopathologic events in experimental diabetic

524

nephropathy: a study in db/db mice, Experimental and molecular pathology, 1980, 33,

525

323-332.

526

(32) Gan, P. Y.; Steinmetz, O. M.; Tan, D. S.; O'Sullivan, K. M.; Ooi, J. D.; Iwakura, Y.;

527

Kitching A. R.; Holdsworth, S. R. Th17 cells promote autoimmune anti-myeloperoxidase

528

glomerulonephritis, J Am Soc Nephrol, 2010, 21, 925-931.

529

(33) Marx, N.; Walcher, D.; Ivanova, N.; Rautzenberg, K.; Jung, A.; Friedl, R.; Hombach, V.;

530

de Caterina, R.; Basta, G.; Wautier, M. P. Wautiers, J. L. Thiazolidinediones reduces

531

endothelial expression of receptors for advanced glycation end products, Diabetes, 2004,

532

53, 2662-2668.

533

(34) Huang, K. P.; Chen, C.; Hao, J.; Huang, J. Y.; Liu P. Q.; Huang, H. Q. AGEs-RAGE

534

system down-regulates Sirt1 through the ubiquitin-proteasome pathway to promote FN

535

and TGF-beta1 expression in male rat glomerular mesangial cells, Endocrinology, 2015,

536

156, 268-279.

537

(35) Wahab, N. A.; Schaefer, L.; Weston, B. S.; Yiannikouris, O.; Wright, A.; Babelova, A.;

538

Schaefer, R.; Mason, R. M. Glomerular expression of thrombospondin-1, transforming

539

growth factor beta and connective tissue growth factor at different stages of diabetic

540

nephropathy and their interdependent roles in mesangial response to diabetic stimuli.

541

Diabetologia. 2005, 48, 2650–2660.

542 543

(36) Wolf, G. Renal injury due to renin-angiotensin-aldosterone system activation of the transforming growth factor-beta pathway. Kidney Int. 2006, 70, 1914–1919. ACS Paragon Plus Environment


Page 26 of 50

26 of 50

544

(37) Hong, S. W.; Isono, M.; Chen, S.; Iglesias-de la Cruz, M. C.; Han, D. C.; Ziyadeh, F. N.

545

Increased glomerular and tubular expression of transforming growth factor-beta1, its type

546

II receptor, and activation of the Smad signaling pathway in the db/db mouse. Am J

547

Pathol. 2001, 158, 1653–1663.

548 549 550

(38) Lane, P. H.; Snelling, D. M.; Langer, W. J. Streptozocin diabetes elevates all isoforms of TGF-beta in the rat kidney. Int J Exp Diabetes Res. 2001, 2, 55–62. (39) Okada, T.; Wada, J.; Hida, K.; Eguchi, J.; Hashimoto, I.; Baba, M.; Yasuhara, A. Shikata,

551

K.;

Makino,

H.

Thiazolidinediones

ameliorate

diabetic

552

cycle-dependent mechanisms. Diabetes, 2006, 55, 1666–1677.

nephropathy

via

cell

553

(40) Patek, C. E.; Fleming, S.; Miles, C.G.; Bellamy, C. O.; Ladomery, M.; Spraggon, L.;

554

Mullins, J.; Hastie, N. D.; Hooper, M. L. Murine Denys-Drash syndrome: evidence of

555

podocyte de-differentiation and systemic mediation of glomerulosclerosis. Hum Mol Genet,

556

2003, 12, 2379–2394.

557

(41) Lee, H. S.; Song, C. Y. Differential role of mesangial cells and podo-cytes in

558

TGF-beta-induced mesangial matrix synthesis in chronic glomerular disease. Histol

559

Histopathol. 2009, 24, 901–908.

560 561

(42) Lee, H. S. Pathogenic role of TGF-beta in the progression of podocyte diseases. Histol Histopathol, 2011, 26, 107–116.

562

(43) Peired, A.; Angelotti, M. L.; Ronconi, E.; la Marca, G.; Mazzinghi, B.; Sisti, A.;

563

Lombardi, D.; Giocaliere, E.; Della Bona, M.; Villanelli, F.; Parente, E.; Ballerini, L.;

564

Sagrinati, C.; Wanner, N.; Huber, T. B.; Liapis, H.; Lazzeri, E.; Lasagni, L.; Romagnani,

565

P. Proteinuria impairs podocyte regeneration by sequestering retinoic acid. J Am Soc

566

Nephrol. 2013, 24, 1756–1768.


Page 27 of 50


27 of 50

567

(44) Zhang, J.; Pippin, J. W.; Krofft, R. D.; Naito, S.; Liu, Z. H.; Shankland, S. J. Podocyte

568

repopulation by renal progenitor cells following glucocorticoids treatment in experimental

569

FSGS. Am J Physiol Renal Physiol. 2013, 304, 1375–1389.

570

(45) Tesch, G. H. Macrophages and diabetic nephropathy. Semin. Nephrol. 2010, 30, 290–301.

571

(46) Chuang, L. Y; Guh, J. Y. Extracellular signals and intracellular pathways in diabetic

572

nephropathy. Nephrology, 2001, 6, 165–172.

573

(47) Schmid, H.; Boucherot, A.; Yasuda, Y.; Henger, A.; Brunner, B.; Eichinger, F.; Nitsche,

574

A.; Kiss, E.; Bleich, M.; Grone, H. J.; Nelson, P. J.; Schlondorff, D.; Cohen, C. D.;

575

Kretzler M. European Renal c, Modular activation of nuclear factor-kappaB transcriptional

576

programs in human diabetic nephropathy, Diabetes, 2006, 55, 2993-3003.

577

(48) Iwamoto, M.; Mizuiri, S.; Arita, M.; Hemmi, H. Nuclear factor-κB activation in diabetic

578

rat kidney: evidence for involvement of P-selectin in diabetic nephropathy. Tohoku J. Exp.

579

Med. 2005, 206, 163–171.

580

(49) Yang, B.; Hodgkinson, A.; Oates, P. J.; Millward, B. A.; Demaine, A. G. High glucose

581

induction of DNA-binding activity of the transcription factor NF-kB in patients with

582

diabetic nephropathy. Biochim. Biophys. Acta Mol. Basis Dis. 2008, 1782, 295-302.

583 584 585 586 587 588

(50) Brownlee, M. Biochemistry and molecular cell biology of diabetic complications, Nature, 2001, 414, 813-820. (51) Moscat, J.; Rennert, P.; Diaz-Meco, M. T. PKCzeta at the crossroad of NF-kappaB and Jak1/Stat6 signaling pathways, Cell death and differentiation, 2006, 13, 702-711. (52) Parveen, A.; Jin, M.; Kim, S. Y. Bioactive phytochemicals that regulate the cellular processes involved in diabetic nephropathy. Phytomedicine, 2018, 39, 146-159.

589

(53) Lim, A. K.; Ma, F. Y.; Nikolic-Paterson, D. J.; Ozols, E.; Young, M. J.; Bennett, B. L.;

590

Friedman, G. C.; Tesch, G. H. Evaluation of JNK blockade as an early intervention ACS Paragon Plus Environment


Page 28 of 50

28 of 50

591

treatment for type 1 diabetic nephropathy in hypertensive rats. Am. J. Nephrol. 2011, 34,

592

337–346.

593 594

(54) Yang, R.; Trevillyan, J. M. c-Jun N-terminal kinase pathways in diabetes. Int. J. Biochem. Cell Biol. 2008, 40, 2702–2706.

595

(55) Cao, H.; Hininger-Favier, I.; Kelly, M. A.; Benaraba, R.; Dawson, H. D.; Coves, S.;

596

Roussel, A. M.; Anderson, R. A. Green tea polyphenol extract regulates the expression of

597

genes involved in glucose uptake and insulin signaling in rats fed a high fructose diet. J

598

Agric Food Chem. 2007, 55(15), 6372-6378.

599

(56) Wang, B. S.; Huang, G. J.; Lu, Y. H.; Chang, L. W. Anti-inflammatory effects of an

600

aqueous extract of Welsh onion green leaves in mice. Food Chem. 2013, 138(2-3),

601

751-756.

602

(57) Chen, H.; Yang, X.; Lu, K.; Lu, C; Zhao, Y.; Zheng, S.; Li, J.; Huang, Z.; Huang, Y.;

603

Zhang, Y.; Liang, G. Inhibition of high glucose-induced inflammation and fibrosis by a

604

novel curcumin derivative prevents renal and heart injury in diabetic mice. Toxicology

605

Letters. 2017, 278, 48–58.

606

607

608

609

610

611


Page 29 of 50


29 of 50

612

613

614

615

616

617

618

Figure legends

619

Figure 1. Effect of TP treatment on fasting blood glucose levels (A), serum insulin levels (B),

620

body weight (C), water consumption (D) and food consumption (E) that were measured once a

621

week after mice were fasted for 12 h before blood collection. Serum insulin levels were

622

measured by ELISA. Each value represents the mean ± SEM (n =10). Values with different

623

letters (a−c) differ from each other significantly (P < 0.05).

624

Figure 2. Effect of TP treatments on insulin resistance, insulin sensitivity and serum lipid

625

levels. (A) HOMA-IR (Homeostasis Model Assessment of Insulin Resistance) = fasting serum

626

insulin (mIU/ml) × fasting plasma glucose (mmol/L)/22.5. (B) HOMA-IS (Homeostasis Model

627

Assessment of Insulin Sensitivity) = 1 / [fasting plasma glucose (mmol/L) × fasting serum

628

insulin (mU/ml) ]. Serum levels of TC (C), TG (D), HDL-C (E), LDL-C (F) after 12 h fasting

629

at the end of the 5-week treatment. Each value represents the mean ± SEM (n = 10); Values

630

with different letters (a−c) differ from each other significantly (P < 0.05).



Page 30 of 50

30 of 50

631

Figure 3. TP treatment ameliorates renal dysfunction in diabetic mice. (A) Representative

632

images of the kidneys in all groups. (B) Kidney/body weight (%) was measured after 5-week

633

treatment. (C) Quantification of total urinary protein excretion (μg/ml) 24 h after each

634

treatment once a week. (D) Representative H&E staining images of the glomerulus (a - NC, b -

635

MC, c - TP, and d - TPR groups; scale bar 20 μm). (E, F) Comparison of the glomerular cell

636

number and glomerular area (μm2) across groups (average of 20 glomeruli per mouse; scale bar

637

20 μm). The data are presented as means ± SEM (n = 10); Values with different letters (a−c)

638

differ from each other significantly (P < 0.05).

639

Figure 4. The effect of TP on urine nitrogen and creatinine in serum. (A) Urine nitrogen in

640

serum; (B) Creatinine in serum; (C) Ratio of urine nitrogen and creatinine. The data are

641

presented as means ± SEM (n = 8); Values with different letters (a−c) differ from each other

642

significantly (P < 0.05).

643

Figure 5. TP ameliorated the structural abnormalities of DN. (A) Representative pictures of

644

IHC of Podocin in kidney sections (a - NC, b - MC, c - TP, and d - TPR groups; scale bar 20

645

μm). (B) Western blotting images showing renal Podocin levels. Quantification of Podocin

646

expression in Western blots (C) and IHC (D). Each value represents the mean ± SEM (n = 8; 4

647

independent experiments); Values with different letters (a−c) differ from each other

648


649

Figure 6. TP prevented diabetes-induced accumulation of AGEs and led to decreased RAGE

650

levels in the glomeruli. (A) Representative pictures of IHC staining of RAGE in kidney

651

sections (a - NC, b - MC, c - TP, and d - TPR groups; scale bar 40 μm). (B) Western blotting

652

images of renal AGE and RAGE levels. (C) Fold increase in renal AGE levels relative to that

653

in NC mice by ELISA. Quantification of RAGE levels in Western blotting (D) and IHC (E). ACS Paragon Plus Environment

Page 31 of 50


31 of 50

654

The data are presented as means ± SEM (n = 9; 3 independent experiments); Values with

655

different letters (a−c) differ from each other significantly (P < 0.05).

656

Figure 7. TP decreased TGF-β1 content in the kidney. (A) Representative pictures of IHC

657

staining of TGF-β1 in kidney sections (a - NC, b - MC, c - TP, and d - TPR groups; scale bar

658

40 μm). (B) Western blotting images of renal TGF-β1 levels. Quantification of TGF-β1 in

659

Western blotting (C) and IHC (D). The data are presented as means ± SEM (n = 9; 3

660

independent experiments); Values with different letters (a−c) differ from each other

661


662

Figure 8. Effect of TP treatment on the NF-κB signaling pathway. (A) Western blotting

663

images of p- PKCζ, PKCζ, p-JNK, JNK, p-NF-κB and NF-κB expression. (B) Relative

664

expression of p-PKCζ, p-JNK and p-NF-κB to PKCζ, JNK and NF-κB levels respectively. The

665

data are presented as means ± SEM (n = 9; 3 independent experiments); Values with different

666

letters (a−c) differ from each other significantly (P < 0.05).

667

Figure 9. Effect of TP treatment on inflammatory factor expression levels. (A) Western

668

blotting images of iNOS and TNF-α. (B) Relative expression of iNOS and TNF-α to β-actin.

669

The data are presented as means ± SEM (n = 8; 4 independent experiments); Values with

670

different letters (a−c) differ from each other significantly (P < 0.05).

671

672

673

674



Page 32 of 50

32 of 50

675

676

677

678

679

680

681

682

683

684

Table 1.

685

The amino acid composition of tea polypeptides and tea protein Amino acid

Content of hydrolyzed amino acid

Content of free amino acid（

（g/100g）

g/100g）

name TP

TPR

TP

TPR

Aspartic acid

1.82±0.05

4.14±0.02

0.32±0.02

Tea Polypeptide Ameliorates Diabetic Nephropathy through RAGE

Recommend Documents